M Spharma Associates Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: M Spharma Associates Pharmaceutical Import Records from India — 2 Products, $415.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M Spharma Associates — Pharmaceutical Importer Profile (2026) | 2 Products, $415.8K Trade | TransData Nexus

M Spharma Associates

Pharmaceutical Importer · Sri Lanka · Gastrointestinal Focus · $415.8K Total Trade · DGFT Verified

M Spharma Associates is a pharmaceutical importer based in Sri Lanka with a total trade value of $415.8K across 2 products in 2 therapeutic categories. Based on 14 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M Spharma Associates sources from 1 verified Indian supplier, with The Madras Pharmaceuticals accounting for 100.0% of imports.

M Spharma Associates — Import Portfolio & Supplier Network

M Spharma Associates import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M Spharma Associates?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
The Madras Pharmaceuticals	$943.5K	47	100.0%

M Spharma Associates sources from 1 verified Indian supplier across 36 distinct formulations. The sourcing is highly concentrated — The Madras Pharmaceuticals accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does M Spharma Associates Import?

Formulation	Value	Ships
Emitop domperidone tablets BP 10	$121.0K	4
Gabanin 300 gabapentin capsules USP 300MG	$88.7K	2
Emitop domperidone tablets 10MG	$73.2K	2
Emitop domperidone tablets 10MG	$73.1K	2
Atorfit 20 atorvastatin tabelts 20	$50.0K	1
Gabanin 300 gabapentin capsules sup 300MG	$50.0K	1
Gabanin 100 gabapentin capsules USP 100MG	$50.0K	1
Emitop domperidone tablets BP 10	$48.9K	3
Abacus 50 acarbose tablets 50	$42.9K	2
Gabanin 100 gabapentin capsules USP	$42.4K	2
Ranosin ranolazine extended releasetablets 500	$38.6K	1
Ranosin ranolazine extended release tablets 500	$38.6K	1
Emitop domperidone tablets BP 10 MG	$36.3K	1
Clobas 10 clobazam tablets BP 10	$27.6K	1
Gabanin 300 gabapentin capsules USP	$22.3K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Domperidone	Gastrointestinal	$372.9K	12	1.3%	10
2	Acarbose	Advanced Diabetes Medications	$42.9K	2	0.6%	14

M Spharma Associates imports 2 pharmaceutical products across 2 categories into Sri Lanka totaling $415.8K.

M Spharma Associates — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M Spharma Associates is a pharmaceutical importer and buyer based in Sri Lanka, specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a key player in the Sri Lankan pharmaceutical distribution network, focusing on the importation of specific therapeutic products to meet local healthcare needs. While detailed information about its parent company and exact headquarters location is not publicly available, M Spharma Associates plays a significant role in ensuring the availability of essential medications within the Sri Lankan market.

2Distribution Network

Specific details regarding M Spharma Associates' warehouse locations and logistics capabilities are not publicly disclosed. However, as a pharmaceutical importer, the company likely collaborates with established logistics providers to ensure efficient distribution across Sri Lanka. The geographic coverage of its distribution network is presumed to encompass major urban centers and healthcare facilities nationwide, facilitating timely access to imported pharmaceutical products.

3Industry Role

M Spharma Associates functions primarily as a pharmaceutical importer and buyer within Sri Lanka's supply chain. By sourcing finished pharmaceutical formulations from India, the company contributes to the diversification and availability of medications in the local market. Its role is crucial in bridging the gap between international pharmaceutical manufacturers and the Sri Lankan healthcare system, ensuring that a variety of therapeutic options are accessible to meet patient needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M Spharma Associates

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

M Spharma Associates demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single Indian supplier, The Madras Pharmaceuticals. This single-source dependency may pose risks related to supply chain disruptions, such as production delays or regulatory changes affecting the supplier. The consistent volume of shipments—47 in total—suggests a stable and ongoing relationship between M Spharma Associates and The Madras Pharmaceuticals, indicating mutual trust and reliability. However, the lack of diversification in sourcing could limit the company's ability to adapt to market changes or negotiate better terms.

2Supply Chain Resilience

The resilience of M Spharma Associates' supply chain is closely tied to its exclusive reliance on The Madras Pharmaceuticals. The absence of backup suppliers means that any disruption at The Madras Pharmaceuticals could significantly impact M Spharma Associates' ability to meet market demand. The limited diversity in imported formulations—36 unique products—may also restrict the company's capacity to offer a broader range of therapeutic options. Additionally, the reliance on a single shipping route exposes the supply chain to potential logistical challenges. Ensuring that The Madras Pharmaceuticals adheres to international Good Manufacturing Practices (GMP) and maintains robust regulatory compliance is essential to mitigate these risks.

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing pharmaceutical imports in Sri Lanka. Established under the NMRA Act No. 5 of 2015, the authority is responsible for ensuring the safety, efficacy, and quality of medicinal products available in the country. Key legislation governing pharmaceutical imports includes the Medicines (Pricing Mechanism for Medicines) Regulations, which stipulate the procedures for pricing and importation of medicines. The marketing authorization pathway for Indian generics involves obtaining approval from the NMRA, which includes submitting comprehensive documentation and undergoing inspections to verify compliance with Sri Lankan standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Sri Lanka are stringent. Importers must obtain an import license from the NMRA, which involves submitting detailed information about the products, including their origin, composition, and intended use. The NMRA requires that all imported pharmaceutical products be manufactured in facilities adhering to Good Manufacturing Practices (GMP). Recognized GMP certifications include those issued by the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers possess valid GMP certificates to comply with Sri Lankan regulations.

M Spharma Associates — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

M Spharma Associates focuses on importing pharmaceutical products in the gastrointestinal and advanced diabetes medication categories. The substantial import value of Domperidone, a gastrointestinal medication, indicates a strong market demand for such treatments in Sri Lanka. The inclusion of Acarbose, an advanced diabetes medication, reflects the company's strategy to address the growing prevalence of diabetes in the region. This targeted approach suggests that M Spharma Associates is aligning its product offerings with the therapeutic needs of the Sri Lankan population.

2Sourcing Profile

M Spharma Associates' sourcing strategy is centered on importing generic drugs from India, focusing on specific formulations that cater to prevalent health conditions in Sri Lanka. The company's preference for finished pharmaceutical formulations over raw Active Pharmaceutical Ingredients (APIs) indicates a commitment to ensuring product quality and compliance with local regulations. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for M Spharma Associates' procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to M Spharma Associates

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with M Spharma Associates. The company's current sourcing pattern, characterized by a concentrated supplier base, suggests potential for diversification. Indian exporters can explore this opportunity by offering competitive products that align with M Spharma Associates' therapeutic focus areas. Establishing a relationship with M Spharma Associates could lead to a more resilient and diversified supply chain, benefiting both parties.

2Requirements & Qualifications

Indian exporters seeking to supply M Spharma Associates and the Sri Lankan market must ensure that their products are registered with the NMRA and comply with local regulations. This includes obtaining necessary import licenses, adhering to GMP standards recognized by the NMRA, and ensuring that products meet quality and labeling requirements. Additionally, exporters should be prepared to provide comprehensive documentation, including Certificates of Analysis, batch release certificates, and material safety data sheets, to facilitate the import process.

3How to Approach

Frequently Asked Questions — M Spharma Associates

What products does M Spharma Associates import from India?

M Spharma Associates imports 2 pharmaceutical products across 2 categories. Top imports: Domperidone ($372.9K), Acarbose ($42.9K).

Who supplies pharmaceuticals to M Spharma Associates from India?

M Spharma Associates sources from 1 verified Indian suppliers. The primary supplier is The Madras Pharmaceuticals (100.0% of imports, $943.5K).

What is M Spharma Associates's total pharmaceutical import value?

M Spharma Associates's total pharmaceutical import value from India is $415.8K, based on 14 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M Spharma Associates focus on?

M Spharma Associates imports across 2 categories. The largest: Gastrointestinal (89.7%), Advanced Diabetes Medications (10.3%).

Get Full M Spharma Associates Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.